FINNENCE ▪ THE WIRE FILE

THE WIRE · № 81058

News■ Unclear/unknown

Iambic Therapeutics prices IPO at $16 per share on Nasdaq

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-14 23:08 UTC · LAST UPDATE 2026-10-16 21:56 UTC

KINDNews

DIRECTION■ Unclear/unknown

SOURCES1

ENTITIES2

STORY SIZE20 RECORDS

FIRST SEEN2026-10-14 23:08 UTC

LAST UPDATE2026-10-16 21:56 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

An IPO pricing at $16 is a small-cap listing with limited read-through to broader healthcare.

Minor biotech IPO, narrow relevance

CATALYST TO WATCH

First-day trading performance

MAIN RISK

Post-IPO price weakness

02 THE STORY SO FAR

THE RECORD, IN ORDER.

UPDATED 20 TIMES · FIRST 2026-10-14 23:08 UTC · LAST 2026-10-16 21:56 UTC

2026-10-14 23:08 UTCNewsIambic Therapeutics prices IPO at $16 per share on NasdaqCURRENT RECORD

2026-10-15 00:13 UTCNewsIambic, an AI drug discovery specialist, banks $150M in an IPO

2026-10-15 06:07 UTCNewsIAM IPO News - Small molecule biotech Iambic Therapeutics prices IPO at $16, the midpoint of the range

2026-10-15 06:30 UTCNewsIambic goes public with $150M IPO to accelerate clinical development of oncology pipeline

2026-10-15 08:18 UTCNewsIambic Therapeutics prices 9.38M share IPO at $16.00/share

2026-10-15 11:55 UTCNewsIambic Therapeutics sets $16 IPO price, targets $150 million raise

2026-10-15 14:04 UTCNewsIambic banks $150M from IPO to advance cancer pipeline

2026-10-15 14:58 UTCNewsIambic Therapeutics stock rises 16% in Nasdaq debut after IPO

2026-10-16 02:53 UTCNewsCity Therapeutics prices IPO at $18 per share, raising $200M

2026-10-16 06:47 UTCNewsCity goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq

2026-10-16 09:40 UTCNewsCity raises $200M in upsized IPO to advance pipeline of RNAi therapies

2026-10-16 10:17 UTCNewsCity Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field

2026-10-16 10:17 UTCNewsUpdated: City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field

2026-10-16 12:47 UTCNewsCTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range

2026-10-16 16:07 UTCNewsRNAi Developer City Therapeutics Jumps 28% After Upsized US IPO

2026-10-16 16:30 UTCNewsIambic CEO on taking an AI drug company public

2026-10-16 17:13 UTCNewsCity Therapeutics surges in market debut after upsizing $200M IPO

2026-10-16 17:48 UTCNewsCity Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver

2026-10-16 21:44 UTCNewsIPO News - US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week’s pricings

2026-10-16 21:56 UTCNewsCity Therapeutics' Upsized $200M IPO Joins Biotech Wave

03 WHO'S INVOLVED

ENTITIES ON FILE.

SUBJECTNasdaq Composite · ^IXIC

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01googlenewsnews.google.com · PRIMARY2026-10-14 23:08 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←CORRELATIONshares ^IXIC
Nasdaq Composite -1.9%2026-10-15 00:05 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.